[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636389":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":22,"responsibleParty":37,"collaborators":10,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":10,"maxAge":10,"enrollmentInfo":49,"targetDuration":52,"studyType":53,"phases":10,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":25,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"University Hospital, Geneva","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients with scheduled RYGB at the Geneva University Hospitals",null,"Morbidly obese patients scheduled for Roux-en-Y gastric bypass",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Laurence Genton, MD","CONTACT","0041 79 553 34 84","laurence.genton@hug.ch",{"name":19,"role":15,"phone":20,"phoneExt":10,"email":21},"Laure Wilmart-Beck","0041 22 372 93 49","laure.wilmart@hug.ch",[23],{"facility":24,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":10},"Geneva University Hospitals","RECRUITING","Geneva","Canton of Geneva","1205","Switzerland","CH",{"type":32,"coordinates":33},"Point",[34,35],6.14569,46.20222,{"lat":35,"lon":34},{"type":38,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Genton Graf Laurence","Professor","100636389","can-pre-operative-lean-mass-predict-weight-loss-after-roux-en-y-gastric-bypass-100636389",false,"NCT07565051","Can Pre-operative Lean Mass Predict Weight Loss After Roux-en-Y Gastric Bypass?","FLAG","Inclusion Criteria:\n\n* Patients ≥ 18 years AND\n* Meeting inclusion criteria for RYGB (www.smob.ch): BMI ≥35 kg\u002Fm2, failure of weight-reducing programs over 2 years (for patients with a BMI ≥50 kg\u002Fm2, 1 year), understanding of the necessity to change the lifestyle and eating habits post-operatively, signed consent for lifelong post-operative follow-up in a recognized bariatric center AND\n* Scheduled RYGB at the HUG OR previous RYGB at the HUG with a present follow-up in Clinical Nutrition and dietetics at the HUG AND\n* Understanding French\n\nExclusion Criteria:\n\n* Inability or refusal to give consent.\n* Planification for another type of bariatric surgery than RYGB\n* Contra-indications to bariatric surgery as stated under www.smob.ch: insufficient nutritional knowledge in nutrition to lose weight, pregnancy, kidney failure (Creatinine ≥ 300 umol\u002Fl without dialysis, Crohn's disease, active cancer or remission \\\u003C 2 years, active psychiatric disease, substance abuse (alcohol, cannabis, opioids), absence of compliance, lack of understanding of the requirements and necessary lifestyle changes reported by physician or dietician.","ALL",{"count":50,"type":51},91,"ESTIMATED","5 Years","OBSERVATIONAL","The goal of this observational study is to evaluate whether preoperative fat-free mass predicts post-operative weight loss in patients undergoing Roux-En-Y gastric bypass. The primary objective of this study is to evaluate whether preoperative fat-free mass predicts weight loss in the two years following RYGB.\n\nThe investigators will collect the following data, assessed as part of routine follow-up:\n\n* height, weight, hip and waist circumferences\n* body composition by bioimpedance analysis and dual energy-X-ray absorptiometry\n* Muscle strength and physical activity\n* Nutritional parameters: resting energy expenditure, eating behavior and digestive tolerance\", plasma micronutrient status. .\n* Cardiovascular risk factors: fasting glucose, blood levels of Hb1Ac, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, blood pressure\n* Co-morbidities: joint pain and arthritis, sleep apnea, gastro-oesophageal reflux, metabolic dysfunction-associated fatty liver disease (MAFLD), cancer, stroke, heart attack.\n\nQuality of life: quality of life by the \"Bariatric Analysis and Reporting Outcome (BAROS) questionnaire\", symptoms of dumping syndrome by the \"Sigstad diagnostic score system\" Birthdate, birthweight and term of their children",[56],"Morbid Obesity Requiring Bariatric Surgery",[58,59,60,61,62,63],"obesity","gastric bypass","body composition","bone mineral density","handgrip strength","sarcopenic obesity","2026-05-04",{"date":66,"type":67},"2026-05-08","ACTUAL",{"date":69,"type":67},"2025-08-18",{"date":71,"type":51},"2032-08-18",{"name":5,"class":6},1]